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Abstract
Background: Synthesis of the hemostatic protein von Willebrand factor (VWF) drives 
formation of endothelial storage organelles called Weibel-Palade bodies (WPBs). In 
the absence of VWF, angiogenic and inflammatory mediators that are costored in 
WPBs are subject to alternative trafficking routes. In patients with von Willebrand 
disease (VWD), partial or complete absence of VWF/WPBs may lead to additional 
bleeding complications, such as angiodysplasia. Studies addressing the role of VWF 
using VWD patient–derived blood outgrowth endothelial cells (BOECs) have reported 
conflicting results due to the intrinsic heterogeneity of patient-derived BOECs.
Objective: To generate a VWF-deficient endothelial cell model using clustered regu-
larly interspaced short palindromic repeats (CRISPR) genome engineering of blood 
outgrowth endothelial cells.
Methods: We used CRISPR/CRISPR-associated protein 9 editing in single-donor 
cord blood–derived BOECs (cbBOECs) to generate clonal VWF−/− cbBOECs. Clones 
were selected using high-throughput screening, VWF mutations were validated by 
sequencing, and cells were phenotypically characterized.
Results: Two VWF−/− BOEC clones were obtained and were entirely devoid of WPBs, 
while their overall cell morphology was unaltered. Several WPB proteins, including 
CD63, syntaxin-3 and the cargo proteins angiopoietin (Ang)-2, interleukin (IL)-6, and 
IL-8 showed alternative trafficking and secretion in the absence of VWF. Interestingly, 
Ang-2 was relocated to the cell periphery and colocalized with Tie-2.
Conclusions: CRISPR editing of VWF provides a robust method to create VWF- defi-
cient BOECs that can be directly compared to their wild-type counterparts. Results 
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1  | INTRODUC TION
Von Willebrand factor (VWF) is a large multimeric protein that plays 
a central role in vascular homeostasis. VWF is synthesized by en-
dothelial cells (ECs) and megakaryocytes and secreted VWF medi-
ates adhesion of platelets to sites of vascular damage and acts as 
a carrier for coagulation factor VIII.1 The importance of synthesis 
and secretion of VWF is highlighted by the bleeding disorder von 
Willebrand disease (VWD), which is caused by mutations in the VWF 
gene that lead to either qualitative or (full or partial) quantitative de-
ficiencies in VWF.2 Elevated levels of VWF, on the other hand, have 
been associated with increased risk of thrombosis.3
Following its synthesis in ECs, VWF is stored in rod-shaped 
storage organelles, called Weibel-Palade bodies (WPBs), where it is 
stored together with a wide variety of inflammatory and angiogenic 
mediators.4‒6 VWF is the driving force behind the formation of its 
own storage organelle, illustrated by the lack of WPBs in ECs from 
a patient with severe VWD type 37 or from VWF null animal mod-
els8‒10 and the formation of pseudo-WPBs upon heterologous ex-
pression of VWF in other cell types.11‒13 Upon endothelial triggering, 
that is, after vascular damage, WPBs undergo exocytosis and deliver 
their cargo to the cell surface or into the vascular lumen, leading to 
the formation of long VWF strings to which platelets and also leuko-
cytes and erythrocytes can adhere.14‒18
Absence of WPBs not only compromises the hemostatic re-
sponse of the endothelium but also has consequences for other se-
cretory cargo that relies on WPBs for proper delivery to and across 
the plasma membrane. Trafficking of several inflammatory media-
tors, including P-selectin, CD63, and chemokines such as interleukin 
(IL)-6 and IL-8, is likely to depend on VWF synthesis and WPB forma-
tion.19 This is underscored by impaired leukocyte rolling and neutro-
phil infiltration in wounds in VWF−/− mice, resulting from defective 
translocation of P-selectin and/or CD63.8,20‒22 In addition, storage 
and secretion of another WPB cargo protein, the proangiogenic 
mediator angiopoietin (Ang)-223‒25 is also disturbed when ECs are 
depleted of VWF.26 Continuous release of Ang-2 as a consequence 
of the unavailability of its default storage compartment has been 
proposed as one of the underlying mechanisms behind angiodyspla-
sia, a clinical complication of VWD that is characterized by recurrent 
bleeding in the gastrointestinal tract and is associated with vascu-
lar malformations of the gut.27,28 However, studies into angiogenic 
properties of blood outgrowth endothelial cells (BOECs) derived 
from patients with VWD, which can be regarded as endothelial mod-
els of VWD, have failed to unequivocally support this model.7,26,29,30
Variation in the genetic background between patients as well 
as controls may be at the basis of the discrepancy between out-
comes in BOECs derived from different individuals. This is further 
confounded by the broad spectrum of VWD-causing mutations 
and the residual VWF expression levels that are associated with 
these mutations.31 To overcome this, there is a need for targeted 
genetic strategies for long-term complete ablation of VWF in 
human primary ECs. Others have previously used the clustered 
regularly interspaced short palindromic repeats (CRISPR)/CRISPR-
associated protein 9 (Cas9) system to target gene expression in 
ECs in vitro.32,33 In this study, we used CRISPR-Cas9 genetic engi-
neering to knock out VWF expression using guide RNAs that tar-
get the first exon of the VWF gene. For this we used cord blood 
outgrowth endothelial cells (cbBOECs) from a single donor, with 
which we created multiple VWF-deficient and control BOEC 
clones with an identical genetic background. cbBOECs possess an 
increased expansion potential compared to other primary ECs,34 
which allowed for prolonged culturing and clonal expansion after 
single-cell sorting that are necessary to generate genetically ho-
mogenous populations of VWF null cells. True VWF−/− cbBOECs 
obtained with our model system confirmed alternative trafficking of several WPB 
proteins in the absence of VWF and support the theory that increased Ang-2/Tie-2 
interaction contributes to angiogenic abnormalities in VWD patients.
K E Y W O R D S
endothelial cells, gene knockout techniques, protein transport, secretory vesicles, von 
Willebrand factor
Essentials
• Von Willebrand factor (VWF) synthesis is essential for the formation of the Weibel-Palade Bodies (WPBs).
• Patient-derived endothelial cell models of von Willebrand disease and VWF deficiency have shown a high degree of phenotypic 
heterogeneity.
• We generated VWF knockout endothelial cells (ECs) using clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-
associated protein 9 gene editing on cord blood outgrowth ECs (cbBOECs).
• WPB-associated proteins show alternative localization in the absence of VWF, and angiopoietin (Ang)-2 colocalizes with the receptor 
Tie-2.
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were selected using a high-throughput screen for loss of VWF 
secretion, and VWF mutations were validated by Sanger and 
next-generation sequencing (NGS). Morphologic, functional, and 
proteomic analyses were used to confirm that CRISPR-engineered 
BOECs retained their endothelial properties. We used this model 
of VWF deficiency to study alternative trafficking of proteins that 
are normally trafficked via WPBs. Upon the absence of WPBs, we 
observed an alternative localization pattern for proteins normally 
associated with the WPB membrane, such as CD63 and the reg-
ulator of WPB exocytosis, syntaxin-3. Alternative targeting was 
also seen for IL-6, IL-8, and Ang-2, which led to altered storage and 
secretion of these WPB cargo proteins in VWF−/− BOECs.
2  | METHODS
2.1 | Antibodies and reagents
Antibodies used in this study are listed in Table S1.
2.2 | Isolation of cbBOECs and cell culture
Cord blood was collected from umbilical veins within 48 hours 
after delivery and was processed for BOEC isolation essentially as 
described before.35 cbBOECs were cultured in EC growth medium 
(EGM)-2 (Lonza, Basel, Switzerland, CC-3162) supplemented with 
18% fetal calf serum (EGM-18; Bodinco, Alkmaar, The Netherlands).36 
Human embryonic kidney 293T (HEK293T) cells were cultured in 
Gibco Dulbecco's Modified Eagle Medium, high glucose, pyruvate 
(ThermoFisher, Landsmeer, The Netherlands) for regular passing and 
seeding and in EGM-18 for virus production.
2.3 | Lentiviral CRISPR‐Cas9 targeting constructs
Guide RNA (gRNA) sequences targeting the first exon of VWF were 
designed using the MIT CRISPR design tool (http://crispr.mit.edu)37 
and the BROAD Institute single guide RNA (sgRNA) designer (http://
www.broadinstitute.org/rnai/public/analysis-tools/sgrna-design)38 
by submitting the DNA sequence of VWF exon 1 flanked by 100 bp 
up- and downstream (chromosome 12, 6123020-6123259 positive 
strand; Figure 1). gRNA sequences were selected that have a high 
predicted efficiency (BROAD Institute score) and a high inverted off-
target score (MIT CRISPR design tool).37,38 gRNAs used in this study 
were gRNA-1: 5′-TGGCCCTCATTTTGCCAGGT-3′ and gRNA-2: 5′-
AGCACCCCGGCAAATCTGGC-3′. Complementary oligos were hy-
bridized with BsmBI restriction site compatible overhangs on either 
side (gRNA-1: 5′-CACCGTGGCCCTCATTTTGCCAGGT-3′ and 5′-
AAACACCTGGCAAAATGAGGGCCAC-3′, gRNA-2: 5′-CACCGAGC 
ACCCCGGCAAATCTGGC-3′ and 5′-AAACGCCAGATTTGCCGGGG 
TGCTC-3′) to facilitate cloning into BsmBI-digested LentiCRISPR 
v2 plasmid39 (a gift from Feng Zhang, Addgene #52961). The re-
sulting constructs LentiCRISPR-gRNA-1 and LentiCRISPR-gRNA-2 
were verified by DNA sequencing analysis.
2.4 | Generation of CRISPR‐edited VWF−/− cbBOECs
Lentivirus production in HEK293T cells and transduction of ECs was 
performed as described.36 cbBOECs (passage number: 4, conflu-
ency: 60%-80%) were lentivirally transduced with LentiCRISPR v2 as 
a control (LentiCRISPR-CTRL), LentiCRISPR-gRNA-1, LentiCRISPR-
gRNA-2 or a combination of LentiCRISPR-gRNA-1 and LentiCRISPR-
gRNA-2 in 6-well plates (Figure 1). After selection using 1 μg/mL of 
puromycin for 72 hours, cells were left to recover until confluency. 
Cells of each condition were single-cell sorted into gelatin-coated 
96-well plates by fluorescence-activated cell sorting (FACS) using a 
BD FACSAria III cell sorter (BD Biosciences, Breda, The Netherlands) 
and using anti-vascular endothelial (VE) cadherin–fluorescein isothi-
ocyanate as an EC marker. EGM-18 was replaced every 2 to 3 days, 
and after 7 days colonies started to form in some wells. Conditioned 
media of wells that were >50% confluent were assayed using VWF 
ELISA40 to identify candidates no longer secreting VWF. VWF-de-
ficient wells were passaged and expanded for further analysis in-
cluding immunoblotting of cell lysates and Sanger sequencing and 
NGS of the genomic DNA isolated with the DNeasy Blood & Tissue 
kit (Qiagen, Venlo, The Netherlands). Verified clones were cryopre-
served as described.35
2.5 | Secretion assay
ECs were seeded in gelatin-coated 6-well plates and cultured at full 
confluency for 4 to 5 days. Twenty-four hours before the secretion 
assay, media were replaced for fresh EGM-18 supplemented with 
10 ng/mL of IL-1β (I9401, Sigma-Aldrich, St Louis, MO) or vehicle. 
Twenty-four-hour conditioned media were harvested, cells were 
pretreated for 15 minutes with serum-free M199 medium (Gibco 
22340, ThermoFisher) supplemented with 0.2% (w/v) bovine serum 
albumin (BSA; Serva, Heidelberg, Germany) and were stimulated 
with 100 μmol/L of histamine or vehicle for 30 minutes as described 
previously.41 Releasates were collected, and stimulated and un-
stimulated ECs were lysed in M199 with 0.2% BSA and 1% Triton 
X-100 (Sigma-Aldrich). Protein secretion and intracellular content 
were determined using the DuoSet ELISA kit for Ang-2 (DY623; R&D 
Systems, Minneapolis, MN), and the Pelikine compact kit for IL-6 and 
IL-8 (M1916 and M1918, respectively; Sanquin, Amsterdam, The 
Netherlands). Assays were performed according to manufacturer's 
protocol.
2.6 | Statistical analysis
Statistical analyses were performed in Prism 8.1.1 (GraphPad 
Software, La Jolla, CA). Normal distribution of the data (N = 3) was 
confirmed using the Shapiro-Wilk test. In case of 1 dependent and 
1 independent variable, a 1-way analysis of variance (ANOVA) was 
used with a Tukey's multiple comparisons test and Bonferroni cor-
rection method for multiple testing. In case of 2 independent vari-
ables, a 2-way ANOVA was used with Tukey's multiple comparisons 
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test and Bonferroni-Dunn correction method for multiple testing. 
Significance values are specified in figure legends.
2.7 | Mass spectrometry
Cells were lysed, processed into tryptic peptides and analyzed by 
mass spectrometry using an Orbitrap Fusion Tribid mass spectrom-
eter (ThermoFisher). Data were processed using the Maxquant com-
putational platform essentially as described.42 The .raw MS files and 
search/identification files obtained with MaxQuant were deposited 
in the ProteomeXchange Consortium via the PRIDE partner re-
pository with the data set identifier PXD013857. A more detailed 
description of the mass spectrometry sample acquisition and data 
analysis is provided in Data S1.
3  | RESULTS
3.1 | Generation of CRISPR/Cas9 mediated VWF 
knockout cord blood outgrowth endothelial cells
Two gRNAs (gRNA-1 and gRNA-2) were designed to target the 
first exon of VWF and were cloned into the lentiviral LentiCRISPR 
expression vector (Figure 1), which simultaneously expresses 
gRNAs and the double strand break inducing Cas9 endonuclease. 
cbBOECs were transduced with LentiCRISPR without targeting 
gRNA (CTRL), gRNA-1, gRNA-2, or a combination and were then se-
lected for effective virus transduction by puromycin. Introduction 
of double strand breaks using CRISPR/Cas9 gene editing gener-
ally results in a heterogeneous pattern of insertions and deletions, 
which may not all lead to knockouts. To enable separation and iso-
lation of biallelic knockouts from the pool of cells that most likely 
also contains nonedited and monoallelic knockouts, we single-cell 
sorted the transduced cells and grew them up in 96-well plate 
format. We performed a first screen for VWF-deficient clones 
by measuring secreted VWF in conditioned media (Figures 1 and 
2A). From this, we selected 10 clones that lost the capacity to se-
crete VWF, as well as 4 control clones, and expanded those to 
6-well plates. It must be noted that it is important to initially select 
multiple clones, as viability of both control and knockout cells ap-
peared to be decreased in some clones after virus transduction, 
single-cell sorting, and repeated passaging. Immunoblotting was 
used to confirm absence of VWF in cell lysates (Figure 2B). We 
selected 2 knockout (VWF−/− A and VWF−/− B) and 2 control clones 
(CTRL A and CTRL B) with comparable growth characteristics 
and expansion potential, which were then further expanded for 
cryopreservation.
Sanger sequencing and NGS of genomic DNA of the 2 selected 
clones revealed a number of CRISPR-induced mutations, which were 
found directly adjacent to the gRNA hybridization sites (Figure 2C, 
Table S2). One allele of clone VWF−/− A contained a single nucleotide 
insertion (c.13insA), causing a frameshift that leads to a premature 
stop codon in the second exon (p.R5KfsX41). The other allele con-
tained a 184-bp deletion starting at position −169 until position 15 
in exon 1, which led to the removal of its start codon. In line with 
this large deletion, we observed a smaller PCR fragment next to 
the normal-sized fragment when amplifying VWF exon 1 from the 
genomic DNA of this clone (Figure S1). Clone VWF−/− B contained 
the same c.13insA mutation as VWF−/− A on both alleles and pos-
sibly a c.55insA mutation on a single allele, which combined with 
the c.13insA mutation would cause a frameshift causing a prema-
ture stop codon in exon 3 (Figure 2C, Table S2). Other low-frequency 
variants that were picked up by NGS were most probably the re-
sult of sequence read errors (Table S2). These results show that the 
loss of VWF expression is the direct result of targeted mutations 
brought about by CRISPR/Cas9-induced double strand breaks in the 
first exon.
We next sought to confirm that our CRISPR-edited BOEC clones 
had retained their EC characteristics. CTRL and VWF−/− BOEC 
clones all formed confluent monolayers with a typical cobblestone 
morphology (not shown). All clones expressed endothelial markers 
VE-cadherin (CD144; Figure 3) and platelet EC adhesion molecule-1 
(CD31; Figure S2) at cell-cell junctions with no obvious differences 
between VWF−/− and CTRL clones. Immunostainings using a selec-
tion of monoclonal and polyclonal antibodies directed against VWF 
showed normal distribution and morphology of WPBs in CTRL clones 
A and B, whereas VWF−/− clones were completely devoid of WPBs 
or remaining VWF immunoreactivity (Figure 3). Finally, all clones 
were able to form networks in a Matrigel-based morphogenesis 
assay in the presence of vascular endothelial growth factor (VEGF; 
Figure S3A) and maintained LDL uptake capacity (Figure S3B). These 
results show that we have generated VWF null BOEC clones that 
have otherwise preserved their normal endothelial properties.
3.2 | Whole‐proteome analysis of VWF‐
deficient BOEC
To determine whether, apart from morphologic or functional differ-
ences, loss of VWF induces changes in the overall protein expression 
F I G U R E  1   Schematic overview of the CRISPR clone generation workflow. Guide RNAs (gRNAs) were designed to target exon 1 of the 
VWF gene (Step 1) and cloned into a LentiCRISPR V2 vector (Step 2). HEK293T cells were transfected with a vector containing a VWF 
targeting gRNA (gRNA-1 or gRNA-2) or the empty LentiCRISPR vector as a control (CTRL) (Step2). Lentivirus was produced in endothelialcell 
growth medium 18, and medium was transferred to cord blood outgrowth endothelial cells (cbBOECs) from a single donor for transduction 
either directly or after combining medium containing 2 gRNAs, sometimes combining virus containing 2 different gRNAs for increased 
targeting efficiency (Step 4). Transduced cells were selected by puromycin and single-cell sorted using vascular endothelial (VE)-cadherin as 
an endothelial cell surface marker (Step 5). Medium of single-cell clones was collected for an ELISA-mediated high-throughput screen for von 
Willebrand factor (VWF) deficient clones. Putative knockout clones were expanded to multiple larger culture surfaces for western blot (WB) 
and sequencing analysis to confirm biallelic VWF knockout (Step 8), after which they were cryopreserved or used for functional assays
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profile of ECs. We compared expression profiles of 2 independent 
CTRL and 2 independent VWF−/− BOEC clones using label-free mass 
spectrometry–based protein quantification. From this, we quantified 
the abundance of 4371 proteins, of which only a limited number (17) 
was significantly up- or downregulated in VWF−/− BOECs (Figure 4A; 
a separate, side-by-side comparison of the individual clones is shown 
in Figure S4). As expected, the largest difference was seen for VWF, 
further confirming that we knocked out its expression in our CRISPR-
engineered BOECs. Proteins with statistically significant changes in 
expression are shown in Figure 4B, which includes among others 
F I G U R E  2   Screening and mutation analysis of VWF knockout clones. (A) Conditioned medium of single-cell clones that had reached 
>50% confluence was collected, and an ELISA for (secreted) von Willebrand factor (VWF) was performed as a first screen for VWF-deficient 
clones. Arrows indicate control (CTRL) and gRNA targeted clones that were selected for further screening. (B) After selected clones had 
been expanded to 6-well plates and reached confluence, cells were lysed and VWF deficiency was assayed using immunoblotting with 
polyclonal anti-VWF and anti-β-actin as a loading control. Two control clones (CTRL A and CTRL B) and two VWF−/− clones (VWF−/− A and 
VWF−/− B) were selected, as indicated by the arrows. (C) Sanger sequencing and next-generation sequencing on exon 1 of VWF were used to 
identify CRISPR/Cas9-induced mutations. Sanger sequence traces are shown for all clones, and major mutations in both VWF−/− clones are 
indicated in the figure
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VWF–/–
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retinal dehydrogenase 1 (ALDH1A1), nucleoredoxin (NXN), and col-
lagen XII alpha chain (COL12A1) (Figure 4B). In contrast, expression 
of the WPB-associated proteins CD63 and syntaxin-3 (STX3), which 
were represented in our data set, remained unchanged (Figure 4C). 
This suggests that these proteins are still present, although they may 
display alternative localizations in the absence of WPBs. The expres-
sion profiles of a select array of WPB and endothelial markers43 pre-
sented no differences between CTRL and VWF−/− clones (Figure 4C), 
establishing that apart from lacking VWF, these cells have retained 
their endothelial characteristics.
3.3 | Alternative routing of Weibel‐Palade body 
cargo proteins
As genetic ablation of VWF also leads to the absence of WPBs, we 
hypothesized that proteins that are normally stored in or associated 
with these granules would now be subject to alternative trafficking 
pathways, resulting in a change in cellular expression. To test this, 
we investigated the localization of a number of WPB (cargo) proteins 
that are involved in inflammation, angiogenesis, and WPB trafficking 
using immunocytochemistry. In VWF-deficient ECs, 2 chemokines 
that are normally stored in WPBs upon upregulation with IL-1β, IL-6, 
and IL-8, were now primarily found in small punctate structures, 
which may represent small constitutive secretory vesicles and a 
ribbon-like pattern consistent with their accumulation in the Golgi 
(Figure 5A,C).44‒47 Because only a small portion of IL-6 and IL-8 is 
stored inside WPBs,19,46 we addressed whether loss of WPBs has an 
effect on functional release of these cytokines. Therefore, we stimu-
lated CTRL and VWF−/− for 24 hours with IL-1β and assayed their un-
stimulated and histamine-evoked release by ELISA (Figure 5B and D). 
Overall, no significant differences were found in terms of intracel-
lular content or absolute release between control and knockout ECs. 
In VWF−/−, B cytokine release relative to intracellular content ap-
pears to be increased, but not in VWF−/− A. However, the production 
F I G U R E  3   Morphology of VWF−/− cbBOECs is similar to controls and Weibel-Palade bodies are lost. Two control clones (CTRL A and B) 
and two VWF−/− clones (VWF−/− A and B) were fixed after 5 to 7 days of confluence and immunostained with anti-vascular endothelial (VE) 
-cadherin (magenta), mouse monoclonal anti-human VWF (cyan) and rabbit polyclonal anti-hVWF (green). Boxed areas are magnified on the 
right. Scale bars represent 20 μm
CTRL A
VWF (mouse)
VWF–/– A VWF–/– B
VWF (rabbit) VWF (mouse) VWF (rabbit)
VWF (mouse) VWF (rabbit) VWF (mouse) VWF (rabbit)
CTRL BVE-cadherin
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of IL-6 and IL-8 is dramatically increased in all clones upon IL-1β, and 
release over 24 hours is clearly considerably higher than the stored 
fraction. Another trend was visible, which showed that an induc-
tion of cytokine release upon histamine stimulation that was seen 
in CTRL clones was less pronounced in VWF−/− clones, although the 
data showed limited statistically significant differences due to varia-
tion between experiments.
The angiogenesis mediator Ang-2 is another protein that, like 
IL-8, is thought to be coackaged in the WPB during its formation 
at the trans-Golgi network (TGN), possibly through noncovalent 
interaction with VWF.48 Also for Ang-2, we observed a punctate 
pattern in the absence of WPBs, as well as an overall decrease in 
Ang-2 signal (Figure 6). However, whereas the punctae of IL-6 and 
IL-8 were diffusely distributed throughout the cell, Ang-2 shows 
enrichment at cell-cell junctions (Figure 6 see also Figure S5). It 
has been suggested previously that altered angiogenic proper-
ties of ECs lacking VWF may be caused by increased constitutive 
release of Ang-2, which would then lead to autocrine/paracrine 
regulation of Tie-2 signaling.28 In line with this, we observed that 
Ang-2, which in CTRL cells primarily localizes to WPBs and shows 
minimal overlap with Tie-2, is primarily found on Tie-2 positive 
structures that are enriched at cell-cell junctions of VWF−/− cells 
(Figure S5). This suggests that in the absence of its storage com-
partment, constitutively released Ang-2 associates with Tie-2 on 
the plasma membrane. Next, we performed secretion assays with 
the CTRL and VWF−/− clones and measured the Ang-2 concentra-
tion in the releasates vs. the lysates by ELISA. Strikingly, lysates of 
VWF−/− clones contained less Ang-2 than CTRL clones (Figure 6Bi), 
F I G U R E  4   Whole proteome analysis of control and VWF−/− cord blood outgrowth endothelial cells (cbBOECs) reveals limited number 
of differentially expressed proteins. (A) Volcano plot showing differentially expressed proteins in 2 independent CTRL clones (CTRL I 
and II) and 2 independent VWF−/− clones (VWF−/− I and II), determined in triplicate. Difference in expression is shown on the x-axis and 
the logarithmic P value (−log10 [P value]) is shown on the y-axis. Significance cutoff line is based on false discovery rate (FDR) = 0.05 and 
S0 = 1.0. Highlighted data points represent VWF (red), Weibel-Palade body (WPB) proteins (purple), proteins downregulated in VWF−/− 
(yellow), proteins upregulated in VWF−/− (green), and several unchanged endothelial markers (blue). (B) Table listing proteins that were 
significantly differentially expressed in VWF−/− BOECs compared to CTRL BOECs, and their corresponding difference in expression, shown 
in the same color coding as (A). (C) Expression profile plots showing label-free quantification (LFQ) (log2) values of VWF, WPB-associated 
proteins CD63, IGFBP7, and syntaxin-3 (STX3) and several well-established endothelial markers: endothelial protein C receptor (EPCR), 
intracellular adhesion molecule 2 (ICAM2), vascular endothelial growth factor receptor 2 (VEGFR2), integrin β3, Tie-1, and vascular 
endothelial (VE)-cadherin. LFQ plots of a selection of the hits in 4B are also shown: retinal dehydrogenase (ALDH1A1), collagen XII alpha 
(COL12A1), dipeptidyl peptidase 4 (DPP4), heat shock protein beta 6 (HSP6B), nucleoredoxin (NXN) and inactive phospholipase C-like 
protein (PLCL1). Triplicates of individual clones are represented as CTRL I (brown diamonds) and CTRL II (red squares), VWF−/− I (dark-blue 
triangles), VWF−/− II (light-blue circles)
10
VWF EPCR ICAM2 integrin β3
34
32
30
28
26
24
CTRL VWF –/– CTRL VWF –/–
40
35
LF
Q 
(lo
g2
)
LF
Q 
(lo
g2
)
CD63
IGFBP7
syntaxin-3 HSPB6 NXN PLCL1
32
30
28
26
24
22
30
28
26
24
22
20
Tie-1
ALDH1A1 COL12A1 DPP4
36
34
32
30
28
26
VE-cadherin VEGFR2
34
32
30
28
26
24
CTRL VWF –/–
LF
Q 
(lo
g2
)
34
32
30
28
26
24
CTRL VWF –/– CTRL VWF –/–
LF
Q 
(lo
g2
)
34
32
30
28
26
24
CTRL VWF –/–
LF
Q 
(lo
g2
)
CTRL VWF –/–
LF
Q 
(lo
g2
)
30
28
26
24
22
20
CTRL VWF –/–
LF
Q 
(lo
g2
)
CTRL VWF –/–
LF
Q 
(lo
g2
)
34
32
30
28
26
24
CTRL VWF –/–
LF
Q 
(lo
g2
)
LF
Q 
(lo
g2
)
34
32
30
28
26
24
CTRL VWF –/–
LF
Q 
(lo
g2
)
34
32
30
28
26
24
CTRL VWF –/–
LF
Q 
(lo
g2
)
34
32
30
28
26
24
CTRL VWF –/–
LF
Q 
(lo
g2
)
34
32
30
28
26
24
CTRL VWF –/–
LF
Q 
(lo
g2
)
34
32
30
28
26
24
CTRL VWF –/–
LF
Q 
(lo
g2
)
34
32
30
28
26
24
CTRL VWF –/–
LF
Q 
(lo
g2
)
30
25
20
–
lo
g1
0 
(P
 
va
lu
e)
(A) (C)
(B)
5
0
–10
Gene
VWF
ALDH1A1
MYH14
EDIL3
SPTAN1
RAB11B
YIPF5
MMP1
DPP4
NXN
TPM4
PLCL1
ALDH1A2
COL12A1
HSPB6
HBA1
HBB
von Willebrand factor 12.13
4.12
3.78
2.46
2.46
2.38
2.28
–1.87
–1.87
–2.00
–2.18
–2.31
–2.45
–2.59
–3.01
–3.02
–4.09
Retinal dehydrogenase 1
Myosin heavy chain 14
EGF-like repeat and discoidin I-like domain-containing protein 3
Spectrin alpha chain, non-erythrocytic 1
Ras-related protein Rab11B
YIP1 family member 5
Interstitial collagenase
DipeptidyI peptidase 4
Nucleoredoxin
Tropomyosin alpha-4 chain
Inactive phospholipase C-like protein 1
Retinal dehydrogenase 2
Collagen alpha-1(XII) chain
Heat shock protein beta-6
Hemoglobin subunit alpha
Hemoglobin subunit beta
Protein Difference (VWF –/– vs CTRL)
Difference
0 10
726  |     SCHILLEMANS Et AL.
F I G U R E  5   Interleukin (IL)-6 and IL-8 
show alternative localization in VWF−/− 
cord blood outgrowth endothelial cells 
(cbBOECs). (A and C) Two control clones 
(CTRL A and B) and 2 VWF−/− clones 
(VWF−/− A and B) were cultured for 5 to 
7 days after reaching confluence, the 
last 24 hours including 10 ng/mL IL-1β. 
Immunostainings were performed with 
mouse monoclonal anti-human VWF 
(magenta) and (A) anti-IL-6 (cyan) or (C) 
anti-IL-8 (cyan). Boxed areas are magnified 
on the right. Scale bars represent 15 μm. 
(B and D) Cytokine storage and secretion 
in IL-1β–treated CTRL and VWF−/− BOECs. 
IL-6 (Bi) and IL-8 (Di) intracellular content 
were measured by ELISA of lysates. (Bii-iii) 
Steady-state release of IL-6 (Bii-Biii) and 
IL-8 (Dii-Diii) was measured by ELISA in 
24-hour unstimulated release samples and 
was expressed as absolute levels (Bii and 
Dii) or normalized to intracellular content 
(Biii and Diii). (Biv and Div) Stimulus-
induced Ang-2 release was assayed using 
30 minutes of unstimulated vs. histamine-
treated CTRL and VWF−/− BOECs. Data 
are shown as mean ± standard error of 
the mean of 3 independent biological 
replicates, performed in triplo. Statistical 
analysis was 1-way analysis of variance 
with a significance level of *P < 0.05, 
**P < 0.01, ***P < 0.001
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F I G U R E  6   Angiopoietin-2 (Ang-2) localizes to the cell-cell junctions in VWF−/− cord blood outgrowth endothelial cells (cbBOECs). (A) 
Two control clones (CTRL A and B) and 2 VWF−/− clones (VWF−/− A and B) were fixed after 5 to 7 days of confluence and immunostained 
with mouse monoclonal anti-human VWF (cyan), anti-Ang-2 (green) and anti-β-catenin (magenta). Boxed areas are magnified on the 
right. Scale bars represent 10 μm. (B) Dysregulation of Ang-2 storage and secretion in the absence of von Willebrand factor (VWF). (Bi) 
Ang-2 intracellular content was measured by ELISA of lysates. (Bii-iii) Steady-state release of Ang-2 was measured by ELISA in 24-hour 
unstimulated release samples and was expressed as absolute levels (Bii) or normalized to intracellular content (Biii). (Biv) Stimulus-induced 
Ang-2 release was assayed using 30 minutes of unstimulated vs. histamine-treated CTRL and VWF−/− BOECs. Data are shown as mean ± SEM 
of 3 independent biological replicates, performed in triplo. Statistical analysis was one-way analysis of variance with a significance level of 
*P < 0.05, **P < 0.01, ***P < 0.001
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F I G U R E  7   CD63 and syntaxin-3 show loss of localization to elongated vesicles but unaltered pattern on rounded vesicles in VWF−/− cord 
blood outgrowth endothelial cells (cbBOECs). Two control clones (CTRL A and B) and 2 VWF−/− clones (VWF−/− A and B) were fixed after 5 to 
7 days of confluence and immunostained with mouse monoclonal anti-human VWF (magenta) and (A) anti-CD63 (cyan) or (B) anti-syntaxin-3 
(STX3, cyan). Boxed areas are magnified on the right. Scale bars represent 10 μm
(A)
CTRL A
VWF–/– A VWF–/– B
CTRL B
VWF VWF
CD63 CD63
VWF VWF
CD63 CD63
(B)
CTRL A
VWF–/– A VWF–/– B
CTRL B
VWF VWF
STX3 STX3
VWF VWF
STX3 STX3
     |  729SCHILLEMANS Et AL.
while the basal release in 24 hours was increased in VWF−/− B 
(Figure 6Bii), substantiating that in the absence of WPBs Ang-2 
is not stored intracellularly but is continuously released. Both 
VWF−/− clones exhibited higher Ang-2 release relative to intracellu-
lar content compared to CTRL clones (Figure 6Biii). In response to 
histamine, CTRL clones showed a strong increase of Ang-2 release, 
whereas in the VWF−/− clones, Ang-2 release remained unchanged 
to unstimulated cells, suggesting that no Ang-2 is stored in hista-
mine-responsive vesicles. Absolute Ang-2 release in response to 
histamine was indeed decreased in VWF-deficient clones.
A different localization pattern was observed for syntaxin-3 and 
CD63, 2 proteins that are normally found both on WPBs and on en-
dosomes.40,49 It has previously been shown that CD63 is trafficked 
to the WPBs via the endosomal system in an annexin A8- and AP-3–
dependent manner.21,50‒52 As expected, whereas CD63 localization 
to the elongated WPBs is lost in VWF−/− clones, its localization to 
spherical vesicles that are most likely endosomes remains similar 
(Figure 7). Interestingly, syntaxin-3 shows a similar pattern, suggest-
ing that this protein may normally follow a similar route as CD63 to 
arrive at a WPB.
4  | DISCUSSION
In this study, we generated stable VWF knockout ECs using CRISPR/
Cas9 gene editing, resulting in ECs entirely devoid of WPBs. To our 
knowledge, this is the first study to report the ablation of an entire 
organelle using CRISPR/Cas9. A number of studies have previously 
employed CRISPR/Cas9 to knock out expression of targets in ECs. 
In most of those studies, no single-cell selection and clonal expan-
sion was performed, but a bulk population was used in which a 
proportion of the cells may still express the targeted protein.33,53 
Single-cell cloning is needed to arrive at genetically homogeneous 
populations of ECs that have lost expression of the target gene, 
but the extensive passaging involved places high demands on the 
proliferative capacity of modified endothelial cells. Our approach 
was similar to a methodological study in which clonal endothelial 
lines were generated after single-cell sorting of CRISPR-edited 
cbBOECs,32 primary ECs that have increased expansive capacity 
compared other primary ECs such as human umbilical vein ECs or 
peripheral BOECs.34,54 Similar to what we find in our study, clonal 
CRISPR-engineered BOEC lines had retained sufficient expansion 
capacity for downstream experimental applications. As our target 
of interest is a secreted rather than a cell surface protein, we used 
an assay for secreted protein as our initial clone selection followed 
by cell expansion for further clone selection through analysis of 
intracellular protein. For knockout of intracellular, nonsecreted 
proteins of interest, an extra expansion step would be required for 
immediate clone selection through western blotting, as we have 
previously described.52
To ensure that phenotypic differences that we observed are not 
the result of (1) variation in genetic background between donors, 
(2) clonal effects that are not directly linked to the inactivation of 
the target, or (3) clonal expansion of single cells, we used BOECs 
from a single donor, and we selected multiple clones from CRISPR-
edited cells as well as control cells that were subjected to the 
same single-cell sorting and expansion procedure in parallel. Even 
with these precautions, we observed that a substantial number of 
clonal candidates were generated that ceased to expand shortly 
after the clonal selection procedure or that suffered from severely 
reduced proliferative capacity. Whether this is the result of lenti-
viral transduction and/or expression of Cas9 protein or whether 
this is an inherent problem of a primary cell system being pushed 
to the limit of its proliferative capacity by clonal expansion is at 
this point unclear. Careful surveying of a large number of candi-
dates for their proliferative capacity may therefore be necessary 
to generate enough clones for the intended experimental analysis. 
This also complicates the use of (CRISPR-edited) BOECs in assays 
that model angiogenesis, which are highly dependent on prolifer-
ation of ECs, and their outcomes would be influenced by a rapid 
drift in proliferative capacity between individual clones. For that 
particular purpose, it may be more suited to use ECs derived from 
induced pluripotent stem cells (iPSCs). CRISPR/Cas9 gene edit-
ing in iPSCs as well as their differentiation into ECs has been well 
established.55,56
Genetic removal of WPBs revealed alternative trafficking path-
ways for WPB cargo and associated proteins. Contrary to most 
WPB cargo proteins, which are copackaged with VWF in newly 
forming WPBs, CD63 first traffics via the endosomal system, and 
that is why it is not observed in immature WPBs.50,51 We have re-
cently shown that CD63, but also the WPB v-SNARE protein vesi-
cle-associated membrane protein 8 (VAMP8), depend on the AP-3 
complex for their targeting to the WPBs.52 The WPB regulating 
t-SNARE protein syntaxin-3, one of the cognate SNARE partners 
of VAMP8, has also been observed both on WPBs and on round 
vesicles that are most likely endosomes, but how it is trafficked to 
WPBs remains unknown. Interestingly, we observe a similar local-
ization pattern for CD63 and syntaxin-3, with localization to WPBs 
and endosomes in control cells and only to endosomes in VWF−/− 
cells. This shows that syntaxin-3 targeting to endosomes is not de-
pendent on WPBs and is therefore most likely not initiated by a 
journey through the secretory pathway. Instead, it may be directly 
incorporated into the endosomes from the Golgi, from which it will 
then commence its cycling between WPBs, plasma membrane, and 
endosomes in a similar manner as CD63.
Trafficking of the chemokines IL-6 and IL-8, which are incor-
porated directly into WPBs during their formation at the TGN, is 
also substantially altered in the absence of WPBs. This was mainly 
reflected in a loss of the stimulus-sensitive pool of these chemok-
ines in response to agonist triggering (Figure 5B and D). The lack of 
stimulus-induced release of IL-6 and particularly IL-8, which is a po-
tent neutrophil chemoattractant, that we observe in VWF−/− BOECs 
suggests that apart from the direct57 and indirect (via P-selectin 
surface presentation8) role that VWF plays in adhesion of leuko-
cytes, impaired regulated secretion of chemokines could further 
contribute to defects in neutrophil recruitment in the absence of 
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VWF. Many interleukins, including IL-6 and IL-8, have been impli-
cated in cardiovascular disease such as atherosclerosis (reviewed 
in Apostolakis et al58). This raises the question of whether dysreg-
ulated endothelial chemokine release as a result of VWF deficiency 
may also affect atherogenesis. Several studies in murine models 
have indeed shown that VWF-deficient mice are protected from 
experimental atherosclerosis.59‒61 However, firm evidence for a 
similar protective effect in patients with VWD has so far not been 
found (reviewed in62). In vitro IL-6 and IL-8 constitutive secretion 
did not show large differences between CTRL and VWF−/− BOECs 
(Figure 5), which is consistent with previous observations that the 
bulk of newly synthesized IL-6 and IL-8 does not enter WPBs but 
is released via the constitutive secretion pathway.19,46 As far as we 
are aware, no quantitative analyses have been performed on IL-6 
and/or IL-8 levels in VWD patients, but based on our in vitro obser-
vations, the likelihood of these deviating significantly from healthy 
subjects is limited, given that most EC-derived IL-6 or IL-8 is not 
released via the WPBs.
WPBs also facilitate the long-term storage of the angiogenesis 
mediator Ang-2 and ensure its on-demand availability during proan-
giogenic conditions, for instance, in response to triggering of WPB 
release by VEGF.28 Previous studies have also shown altered levels of 
continuous Ang-2 release from ECs from patients with VWD or after 
small interfering RNA–mediated VWF knockdown, which has been 
suggested to be in part the underlying cause of altered angiogenic 
properties of VWD patient–derived BOECs and the angiodysplasia 
that is observed in some patients with VWD.26,30 This hypothesis is 
supported by the current finding that when Ang-2 cannot be stored 
in the WPBs, it no longer appears to localize to storage vesicles but 
is released constitutively (Figure 6). However, a recent study on cir-
culating levels of angiogenic mediators in patients with moderate 
and severe VWD did not find (statistically significant) differences in 
circulating levels of Ang-2 in patients with normal and impaired VWF 
synthesis.63 Secreted Ang-2 takes part in the complex regulation of 
angiogenesis through the interaction with a number of EC surface 
receptor proteins, including Tie-2 and several integrins.64,65 Notably, 
we observed increased colocalization of Ang-2 with Tie-2 at cell-cell 
junctions, which we speculate represents extracellular binding of 
Ang-2 to its receptor. This suggests that the absence of WPBs may 
lead to increased interactions of Ang-2 with its cell surface receptors 
and thereby influence the angiogenic activity of ECs in an autocrine/
paracrine manner. Future studies are needed to further unravel how 
the endothelium dynamically regulates angiogenesis through release 
of angiogenic factors.
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